Medical Devices Australia

Australia Renal Denervation Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Australia Renal Denervation Market Industry Trends and Forecast to 2034: Segmented by (Technology, Product, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Australia · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $6.3 Mn Placeholder estimate
Estimate 2025 $8.0 Mn 1.3% of the global market
Projected 2034 $66.9 Mn 735.4% Adds $58.9 Mn over 9 forecast years
CAGR 2025–2034 26.6% Faster than 97% of 173 Medical Devices markets here
Key players 5
  • Australia is 1.28% of the global market.
  • In APAC, the largest is China at $58.0 Mn.
  • Fastest growing: India at 28.1% a year.
  • Australia ranks 4th of 10 by size in APAC.

Market size projection

Australia

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$58.9 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Renal Denervation Market market size by year, Australia
YearMarket sizeChange that yearSince 2025
2024 (estimate) $6.3 Mn — —
2025 (base) $8.0 Mn +$1.7 Mn —
2026 (forecast) $10.1 Mn +$2.1 Mn +26.6%
2027 (forecast) $12.8 Mn +$2.7 Mn +60.3%
2028 (forecast) $16.3 Mn +$3.4 Mn +102.9%
2029 (forecast) $20.6 Mn +$4.3 Mn +156.9%
2030 (forecast) $26.1 Mn +$5.5 Mn +225.2%
2031 (forecast) $33.0 Mn +$6.9 Mn +311.7%
2032 (forecast) $41.8 Mn +$8.8 Mn +421.2%
2033 (forecast) $52.9 Mn +$11.1 Mn +559.9%
2034 (forecast) $66.9 Mn +$14.1 Mn +735.4%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Australia Renal Denervation Market Analysis at a glance
Market size, 2025$8.0 Mn placeholder estimate
Forecast, 2034$66.9 Mn placeholder estimate
Growth (CAGR), 2025–203426.6% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsTechnology, product and end user (see all)
Key playersMedtronic, Recor Medical (Otsuka), Boston Scientific Corporation, SoniVie, Ablative Solutions (see all)
Regulator in AustraliaTGASource: Therapeutic Goods Administration. Checked 14 Nov 2026.
Active clinical trials3 in AustraliaSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Australia Renal Denervation Market Analysis Executive Summary

Renal denervation uses energy delivered through a catheter to calm nerves near the kidneys and lower hard-to-control high blood pressure.

Key segments of the renal Denervation market include technology (Radiofrequency, Ultrasound and Chemical) and product (Catheters and Generators).

Bar chart: Australia Renal Denervation market size, 2024–2034, placeholder estimates. $6.3 Mn in 2024, $8.0 Mn in 2025 and $66.9 Mn in 2034, 26.6% CAGR.
Australia Renal Denervation market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Australia Renal Denervation Market Dynamics

Market Growth Drivers

Heart disease remains the leading cause of death worldwide. An ageing population, more minimally invasive procedures and strong clinical evidence for newer devices are driving the renal Denervation market.

Opportunity

Less invasive procedures, remote monitoring of implanted devices and rising access to cardiac care in emerging markets give the renal Denervation market room to grow.

Market Restraints

High device prices, the need for trained specialists, reimbursement pressure and product recalls hold back the renal Denervation market.

Competitive Landscape for Renal Denervation Market in Australia

The renal Denervation market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Renal Denervation Market in Australia

Renal Denervation in Australia: rules, payment and research

Medical devices must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied.⁠[1] Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines.⁠[2] ClinicalTrials.gov lists 3 studies on Renal Denervation that are recruiting, active or about to start in Australia.⁠[3] High blood pressure (ages 30–79): 29.3% of adults 30–79 in 2019, the latest WHO figure for Australia.⁠[4]

[1] Therapeutic Goods Administration. Checked 14 Nov 2026.

[2] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.

[4] WHO Global Health Observatory, High blood pressure (ages 30–79) (% of adults 30–79). Retrieved 15 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how renal Denervation products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Australia.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Renal Denervation right now, from free public sources.

Latest research 985 papers since 2021 (worldwide)

  1. Extravascular Renal Denervation for Resistant Hypertension: First-in-Human Study. Hypertension (Dallas, Tex. : 1979), 2026
  2. Sympathovagal Imbalance and Insulin Resistance: The Autonomic Nervous System as a Convergent Therapeutic Target for Breaking a Bidirectional Pathogenic Cycle. Diabetes, metabolic syndrome and obesity : targets and therapy, 2026
  3. Improved time in therapeutic range and reduced medication burden after renal denervation: a nationwide real-world registry. Hypertension research : official journal of the Japanese Society of Hypertension, 2026
  4. Computed tomography-derived optimal fluoroscopic projections to guide renal denervation. Hypertension research : official journal of the Japanese Society of Hypertension, 2026
  5. Blood pressure response to methyldopa as a potential indicator of renal denervation responsiveness in resistant hypertension: a case report. Hypertension research : official journal of the Japanese Society of Hypertension, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, WHO Global Health Observatory, World Bank. Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Renal Denervation in context

Australia compared

  • High blood pressure (ages 30–79): 29.3% of adults 30–79 (2019). World: 33.1% of adults 30–79 (2019). 12th highest of the 15 countries we cover in APAC.[1]
  • Health spending per person: 6,980 US$ per person (2023). World: 1,317 US$ per person (2023). Highest of the 15 countries we cover in APAC.[2]
  • Doctors: 4.09 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). Highest of the 15 countries we cover in APAC.[3]

[1] WHO Global Health Observatory, High blood pressure (ages 30–79) (% of adults 30–79). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 16 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Renal Denervation market in Australia?
Placeholder estimate: about $8.0 Mn in 2025, rising to about $66.9 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Renal Denervation market in Australia growing?
Placeholder estimate: about 26.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Renal Denervation market report cover?
The report splits the market by technology (Radiofrequency, Ultrasound, Chemical), product (Catheters, Generators) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Renal Denervation market?
Key players include Medtronic, Recor Medical (Otsuka), Boston Scientific Corporation, SoniVie and Ablative Solutions.
What is driving the Renal Denervation market?
Heart disease remains the leading cause of death worldwide. An ageing population, more minimally invasive procedures and strong clinical evidence for newer devices are driving the renal Denervation market.
Who regulates Renal Denervation in Australia?
Medical devices must be included in the Australian Register of Therapeutic Goods (ARTG), run by the Therapeutic Goods Administration (TGA), before they can be supplied. Source: Therapeutic Goods Administration. Checked 14 Nov 2026.
How is healthcare paid for in Australia?
Medicare pays for public hospital care and many doctor visits, and the Pharmaceutical Benefits Scheme (PBS) subsidises listed medicines. Source: Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
How many clinical trials on Renal Denervation are running in Australia?
3 studies are recruiting, active or about to start in Australia, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Australia. Retrieved 12 Nov 2026.
What does WHO report for Australia?
High blood pressure (ages 30–79): 29.3% of adults 30–79 in 2019, the latest WHO figure. Source: WHO Global Health Observatory, High blood pressure (ages 30–79) (% of adults 30–79). Retrieved 15 Nov 2026.
How many people in Australia are 65 or older?
18.1% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 16 Nov 2026.
Back to Catalogue

Related Medical Devices reports in Australia

See all

Related on hypertension and cardiovascular

See the topic